Thread by @gudnephron

We kept our promise

We are back with the 2 nd issue of Onconeph
#Onconephrology
12 🔥 articles
40+ authors
Great collaborative effort

@kdjhaveri
@MegSise
@CharuThakar
@ackdonline
@NKF_NephPros
@nkf
@onconephsociety
@UCKidney
@uofcincy
@UCincyMedicine
@ucincipress

🔥Our editorial speaks about the summary of the individual topics.
Paraproteinemia
TMA $
Na/K ⬇️⬆️in Ca
Palliative Rx
HSCT & kidney
Heme cancer & kidney
Paraneoplastic GN
Sickle cell ds
OncoSx and AKI
Anemia & cancer
Anti Ca Rx dosing in CKD
TxP Onconeph

🔥Kidney in dysproteinemia

Exhaustive review by @HerrmannMd @AkazukiNinaMD Dr Seshan
@MayoClinic @WeillCornell

👉Covers entire spectrum of kidney involvement in dysproteinemias
👉Excellent path images to support the manuscript.

VA by @Elena_Cervants

HSCT and kidney
State of art review @renalmyeloma Ala Abudayeh
@HofstraKidney @MDAndersonNews

👉Covers the entire spectrum of HSCT and kidney involvement
AKI
TMA
CKD
Dialysis
KTx in HSCT pts

VA by @CTeodosiu

Paraneoplastic Glomerular Diseases
by @MayuriTrivedi80 Anushaya Jeyabalan @MGHKidneys

In their review demystify the complex topic of paraneoplastic GN

VA by @nephromythri

Hemat Malignancies & Kidney

AKI most frequently occurs in patients with MM (31.8%), f/b those with leukemia (27.5%)/lymphoma (18.8%)

👉Kidney effects
Prerenal AKI
ATI
Renovascular ds
Infiltration with Ca cells,
Obstruction
GN
Electrolyte / acid base

Sickle Cell Disease & Kidney
by @PAmarapurkar @EmoryUniversity
L Roberts, J Navarrete & F El Rassi

👉Spectacular review on kidney and SCD
Screening & neph ref
novel urinary biomarkers, iron chelation Rx
KRT and KTx in SCD

VA by @DTomacruzMD

TMA $

In dept review on TMA covering all lengths and breaths of this complex topic

@RMHUCINEPHRO @kdjhaveri @kamkalantar @hawkssox et al

@UCIrvine @UChicago @HofstraKidney

VA by @edgarvlermamd

OncoSx-Related AKI

A very innovative article on this topic

🔥 compilation by @kkalra_22, W Zafar, David Ortiz
@GeisingerHealth @DukeKidney

Pathogenesis of AKI is multifactorial & determined by pt & Ca-specific factors

👉AKI most common after Sx for GU Ca

VA by @krithicism

Na & K ⬆️⬇️ in Cancer

P Ratanasrimetha @BetterCallSeeth @bdubNephro
@MGHKidneys @MDAndersonNews

A very systematic case based approach to electrolyte disorders

@TheSkeletonKG

VA by @brian_rifkin

Anemia Rx in the Ca pt with CKD & ESKD

@ArashRashidi14 @pranavgarimella J Thakkar A Al-Asaad,T Kharadjian, MN Torres

@CaseKidneys @ucsdnephrology @EinsteinMed

A controversial topic of anemia Rx in pts with kidney ds & Ca

🔥 summary of guidelines

VA by @sophia_kidney

TxP Onconephrology

@nymurakami Allison Weber @vinaynairdo

@MGHKidneys @UCSFNephrology @HofstraKidney

A very 🔥🔥topic - uptodate r/v
Wait times
Screening of Ca post TxP
IS and Ca risk
PTLD
MM/amyloid & KTx
🐘in the room - ICPI post TxP

VA by @sophia_kidney

Palliative Rx for pts With Ca & Kidney ds

Antonio Corona, @PabloGarciaMD @SammyG
@HofstraKidney @StanfordNeph @MGHKidneys

A very systematic primer of approach to palliative Rx.

🔥Highlights
Unpleasant $ Mx
Discussing prognosis & GOC
End of life care

VA by @SRameshMD

Cancer Drug Dosing in CKD & dialysis

Fantastic review on drug dosing of anti neoplastic agents

@anushreeshirali Ben Sprangers
@YaleNephrology @UZLeuven

🔥🔥 overview of eGFR estimation & pharmacokinetic/ dynamic considerations in patients with CKD

VA by @krithicism

Thank you
🔥All authors & reviewers
🔥Entire VA team @Nephro_Sparks @brian_rifkin @nephromythri @edgarvlermamd @krithicism @sophia_kidney @DTomacruzMD @Elena_Cervants @CTeodosiu @SRameshMD

EIC @ackdonline @CharuThakar

@NKF_NephPros @nkf

@ElsevierConnect @ElsevierNews

@threadreaderapp